Cecilia Brown

DocwireNews

The US Food and Drug Administration (FDA) has approved osimertinib (Tagrisso, AstraZeneca) to treat certain adults who have unresectable, stage III non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 (L858R) mutations, as detected by an FDA-approved test. The approval is for patients whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy (CRT).The approval follows a priority review by the FDA. The review was based on results from the <a href="https://www.docwirenews.com/post/a-new-standard-of-care-dr-ramalingam-discusses-laura-results-implications-with-the-two-onc-docs" target="_blank" rel="noopener">phase 3 LAURA trial</a> presented during a <a href="https://www.docwirenews.com/post/phase-3-laura-trial-primary-results-highlighted-in-plenary-session" target="_blank" rel="noopener">plenary session</a> at the <a href="https://www.docwirenews.com/conference/asco-2024-lung-cancers-today" target="_blank" rel="noopener">2024 American Society of Clinical Oncology Annual Meeting</a> by Suresh Ramalingam, MD, of the Winship Cancer Institute of Emory University. The results were also simultaneously published in The New England Journal of Medicine.&ldquo;This approval represents a major breakthrough for patients with stage III, EGFR-mutated lung cancer who will now have the opportunity to benefit from osimertinib,&rdquo; Dr. Ramalingam said in a statement. &ldquo;Patients treated with osimertinib lived without disease progression by more than 3 years in the LAURA trial, and this impressive benefit underscores the importance of diagnosing and testing lung cancer patients as early as possible.&rdquo;The LAURA trial showed that osimertinib reduced the risk of disease progression or death by 84% compared to the placebo (hazard ratio 0.16; 95% CI, 0.10-0.24; P&lt;.001) as assessed by blinded, independent central review. The median progression-free survival (PFS) was 39.1 months in patients who received osimertinib, compared to 5.6 months in those who received placebo.The overall survival (OS) results were immature at the current analysis, with 36% of pre-specified deaths for the final analysis reported, but &ldquo;no trend towards a detriment was observed,&rdquo; according to FDA officials. The trial is continuing to assess OS as a secondary endpoint, AstraZeneca officials said.The most common adverse reactions, including laboratory abnormalities that occurred in at least 20% of patients, were lymphopenia, leukopenia, interstitial lung disease/pneumonitis, thrombocytopenia, neutropenia, rash, diarrhea, nail toxicity, musculoskeletal pain, cough, and COVID-19 infection.The recommended osimertinib dose is 80 mg once daily, with or without food, until disease progression or unacceptable toxicity.Sources: <a href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-osimertinib-locally-advanced-unresectable-stage-iii-non-small-cell-lung-cancer">US FDA</a>, <a href="https://www.astrazeneca.com/media-centre/press-releases/2024/tagrisso-us-approval-in-unresectable-lung-cancer.html">AstraZeneca</a>

Jayme Locke, MD, MPH

Joel M. Topf, MD, FACP

The Promise of Xenotransplantation

NKF Spring Clinical Meetings 2025

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Sacituzimab Govitecan Showed Modest Activity for CNS Metastases

Triple-Negative Breast Cancer

Latest News

FDA Approves Osimertinib For Certain Patients With Unresectable, Stage III EGFR-Mutated NSCLC

EGFR+ NSCLC

The US FDA approved osimertinib (Tagrisso, AstraZeneca) to treat certain adults who have unresectable, stage III non-small cell lung cancer with EGFR mutations.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe